The Monetary Value of Informal Care: Obtaining Pure Time Valuations Using a Discrete Choice Experiment.

abstract：OBJECTIVE:To assess the economic efficiency of meloxicam, a cyclo-oxygenase (COX)-2 selective inhibitor, versus diclofenac and piroxicam in the UK for the treatment of patients with osteoarthritis and the impact on the NHS budget of substituting nonselective NSAIDs with meloxicam. Methods and perspective: A decision an...

journal_title：PharmacoEconomics

authors： Tavakoli M

更新日期：2003-01-01 00:00:00

abstract：BACKGROUND:Healthcare resource use data were collected for 1 year as part of the CAESAR (Canada, Australia, Europe, South Africa) clinical trial, which evaluated the effect of adding lamivudine to treatment regimens containing zidovudine in patients with HIV infection. This study showed that lamivudine-containing regim...

journal_title：PharmacoEconomics

authors： Lacey L,Mauskopf J,Lindrooth R,Pham S,Saag M,Sawyer W

更新日期：1999-01-01 00:00:00

abstract：:A number of recent findings from the literature imply that the value of a QALY varies depending on the concentration or dispersion of that QALY over treated individuals. Given that funding decisions are currently made under either the assumption of distributive-neutrality or some combination of explicit decision crite...

journal_title：PharmacoEconomics

authors： Mortimer D

更新日期：2006-01-01 00:00:00

abstract：:Published estimates for the treatment costs of breast cancer vary widely in methodology, perspective, patient populations and time horizon. We systematically summarized and analysed the published literature on per-patient costs of breast cancer, and highlight the perspectives, populations studied, time horizons and fu...

journal_title：PharmacoEconomics

authors： Campbell JD,Ramsey SD

更新日期：2009-01-01 00:00:00

abstract：:Germany is in a period of transition with regard to healthcare reform. The number and intensity of cost control interventions increased during the last decade in an attempt to contain healthcare expenditure. The German legislature has implemented long term macroeconomic measures such as contribution rate stability and...

journal_title：PharmacoEconomics

authors： Ulrich V,Wille E

更新日期：1996-01-01 00:00:00

abstract：:Patients with schizophrenia suffer numerous relapses and rehospitalizations that are associated with high direct and indirect medical expense. Suboptimal therapeutic efficacy and, in particular, problems with compliance are major factors leading to relapse. Atypical antipsychotic agents offer improved efficacy and a l...

journal_title：PharmacoEconomics

authors： De Graeve D,Smet A,Mehnert A,Caleo S,Miadi-Fargier H,Mosqueda GJ,Lecompte D,Peuskens J

更新日期：2005-01-01 00:00:00

abstract：:Cost-effectiveness analysis (CEA) is one of the main tools of economic evaluation. Every CEA is based on a number of assumptions, some of which may not be accurate, introducing uncertainty. Sensitivity analysis (SA) formalizes ways to measure and evaluate this uncertainty. Specific sources of uncertainty in CEA have b...

journal_title：PharmacoEconomics

authors： Jain R,Grabner M,Onukwugha E

更新日期：2011-04-01 00:00:00

abstract：CONTEXT:This study assesses if, and how, existing methods for economic evaluation are applicable to the evaluation of personalized medicine (PM) and, if not, where extension to methods may be required. METHODS:A structured workshop was held with a predefined group of experts (n = 47), and was run using a modified nomi...

journal_title：PharmacoEconomics

authors： Rogowski W,Payne K,Schnell-Inderst P,Manca A,Rochau U,Jahn B,Alagoz O,Leidl R,Siebert U

更新日期：2015-01-01 00:00:00

abstract：BACKGROUND:Given the limited availability of healthcare resources and the recent introduction of new anti-osteoporosis drugs, the interest in the cost effectiveness of drugs in postmenopausal osteoporosis remains and even increases. OBJECTIVE:This study aims to identify all recent economic evaluations on drugs for pos...

journal_title：PharmacoEconomics

authors： Hiligsmann M,Evers SM,Ben Sedrine W,Kanis JA,Ramaekers B,Reginster JY,Silverman S,Wyers CE,Boonen A

更新日期：2015-03-01 00:00:00

abstract：:Studies have not previously reported the indirect cost burden of multiple sclerosis (MS) from an employer perspective. To compare annual indirect costs between privately insured US employees with MS and matched employee controls. A retrospective analysis of a privately insured claims database containing disability dat...

journal_title：PharmacoEconomics

authors： Ivanova JI,Birnbaum HG,Samuels S,Davis M,Phillips AL,Meletiche D

更新日期：2009-01-01 00:00:00

abstract：:The purpose of this article is to review the literature related to economic outcomes associated with treating allergic rhinitis. A literature review was conducted using 'Medline' and the in-house database of the publishers of this journal for articles published between January 1991 and January 1996. Only 3 cost-outcom...

journal_title：PharmacoEconomics

authors： Kozma CM,Sadik MK,Watrous ML

更新日期：1996-07-01 00:00:00

abstract：OBJECTIVE:To decompose drug spending in Sweden between the years 1990 and 2000. This paper updates a previous study, which looked at the period 1990-1995, by providing an additional 5 years of data (1995-2000) and extending the previous analysis in a number of ways. METHODS:The paper builds on the earlier work that sh...

journal_title：PharmacoEconomics

authors： Gerdtham UG,Lundin D

更新日期：2004-01-01 00:00:00

abstract：BACKGROUND:Probabilistic sensitivity analysis (PSA) in cost-effectiveness analysis involves sampling a large number of realisations of an economic model. For some parameters, we may be uncertain around the true mean values of the variables, but the ordering of the values is known. Typical sampling approaches lack eithe...

journal_title：PharmacoEconomics

authors： Ren S,Minton J,Whyte S,Latimer NR,Stevenson M

更新日期：2018-03-01 00:00:00

abstract：:Non-melanoma skin cancer (NMSC) and actinic keratosis are becoming an increasingly important healthcare problem. There are approximately 1 million cases of NMSC in the US each year, primarily basal cell carcinomas, and the incidence is increasing. Although NMSC is significant in terms of both health risk and the resou...

journal_title：PharmacoEconomics

authors： Higashi MK,Veenstra DL,Langley PC

更新日期：2004-01-01 00:00:00

abstract：BACKGROUND:In Australia, many patients who are initiated on asthma controller inhalers receive combination inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) despite having asthma of sufficiently low severity that ICS-alone would be equally effective and less costly for the government. METHODS:We conducted a ...

journal_title：PharmacoEconomics

authors： Laba TL,Reddel HK,Zwar NJ,Marks GB,Roughead E,Flynn A,Goldman M,Heaney A,Lembke K,Jan S

更新日期：2019-02-01 00:00:00

abstract：:The purpose of this paper is to highlight important considerations in the measurement of health-related quality of life (HR-QOL) in paediatric populations. Considerations specific to the evaluation of HR-QOL in children include children's understanding of the questions being asked, their understanding of their own dis...

journal_title：PharmacoEconomics

authors： Connolly MA,Johnson JA

更新日期：1999-12-01 00:00:00

abstract：AIM:To assess the relative cost effectiveness of escitalopram compared with venlafaxine XR in patients with major depressive disorder (MDD). METHODS:An economic evaluation was conducted alongside a double-blind, multinational, randomised clinical trial and examined the costs and quality of life of 251 patients taking ...

journal_title：PharmacoEconomics

authors： Fernandez JL,Montgomery S,Francois C

更新日期：2005-01-01 00:00:00

abstract：:As a consequence of its prevalence, early onset and chronicity, schizophrenia imposes clinical and economic impediments to healthcare practitioners and society alike. Among the many antipsychotics available to treat the symptoms of this devastating illness, clozapine has emerged and differentiated itself from the othe...

journal_title：PharmacoEconomics

authors： Tse G,Thompson D,Procyshyn RM

更新日期：2003-01-01 00:00:00

abstract：OBJECTIVE:The study objective was to evaluate and compare quality-of-life (QOL) parameters between patients with type 2 (non-insulin-dependent) diabetes mellitus who changed therapy from an oral hypoglycaemic agent (OHA) to insulin and those who remained on an OHA. DESIGN:The World Health Organization Quality of Life ...

journal_title：PharmacoEconomics

authors： Pibernik-Okanović M,Szabo S,Metelko Z

更新日期：1998-08-01 00:00:00

abstract：:Peptic ulcer disease (PUD) is a common medical problem costing billions of dollars annually around the world. Since the availability of the first histamine H2-receptor antagonist, cimetidine, many economic analyses have been conducted to compare the impact of this drug class on resource consumption. H2-Antagonists h...

journal_title：PharmacoEconomics

authors： Tucker PP,Nash DB

更新日期：1994-04-01 00:00:00

abstract：OBJECTIVE:To estimate indirect costs in Spanish ambulatory patients with HIV/AIDS and to identify changes in employment status and their current QOL. METHOD:Information was obtained through 32 interviews/enquiries carried out with ambulatory patients receiving medical attention at Gregorio Marañón and Puerta de Hierro...

journal_title：PharmacoEconomics

authors： Oliva J,Roa C,del Llano J

更新日期：2003-01-01 00:00:00

abstract：:The purpose of this study was to estimate the direct and indirect costs of alcoholism in the Federal Republic of Germany. Direct costs comprised treatment costs, while indirect costs consisted mainly of costs incurred as a result of work time lost, as well as costs related to premature retirement and premature mortali...

journal_title：PharmacoEconomics

authors： Brecht JG,Poldrugo F,Schädlich PK

更新日期：1996-11-01 00:00:00

abstract：:Recent studies have shown that ACE inhibitors reduce morbidity and mortality after myocardial infarction (MI). While these trials have obvious clinical implications, the widespread introduction of a new treatment for a condition as common as MI also has clear cost implications. The results of the post-MI studies with ...

journal_title：PharmacoEconomics

authors： Hummel S,Piercy J,Wright R,Davie A,Bagust A,McMurray J

更新日期：1997-08-01 00:00:00

abstract：:The symptoms of onychomycosis and their impact on personal appearance are important determinants of patients' perceptions of their own health. The effect of onychomycosis is greater on psychosocial than physical functioning and is directly related to the extent of nail involvement. This review identified a number of d...

journal_title：PharmacoEconomics

authors： Shaw JW,Joish VN,Coons SJ

更新日期：2002-01-01 00:00:00

abstract：:This willingness-to-pay (WTP) analysis is the first study of its kind undertaken in Australia to support an application for listing of a new drug on the Australian national formulary. The technique offers the advantage of being able to summarise diverse outcomes of therapy in a single unit of measure. Willingness to p...

journal_title：PharmacoEconomics

authors： Davey P,Grainger D,MacMillan J,Rajan N,Aristides M,Dobson M

更新日期：1998-03-01 00:00:00

abstract：:The objective of this study was to demonstrate the cost effectiveness of long term maintenance treatment with citalopram versus standard therapy (defined as short term antidepressant treatment) in patients with major depression in Germany. We chose doxepin, amitriptyline and trimipramine as standard therapy because th...

journal_title：PharmacoEconomics

authors： Nuijten MJ,Hardens M,Souêtre E

更新日期：1995-08-01 00:00:00

abstract：:Measuring health-related quality of life in patients with cancer has focused primarily on the development of reliable and valid instruments (questionnaires), and on the effect of chemotherapy in phase III clinical trials. From this research several important lessons have emerged, such as: (i) the need to measure multi...

journal_title：PharmacoEconomics

authors： Osoba D

更新日期：1995-04-01 00:00:00

abstract：:The objective of this study was to compare the cost effectiveness of amoxicillin/clavulanic acid with other antibacterial regimens for prophylaxis of infection after elective abdominal or gynaecological surgery. Data from 21 previously published comparative clinical trials were used to calculate statistical confidence...

journal_title：PharmacoEconomics

authors： Davey PG,Parker SE,Crombie IK,Jaderberg M

更新日期：1995-04-01 00:00:00

abstract：OBJECTIVE:The objective of this article was to summarize the findings of all the available studies on alternative pharmacological treatments for asthma and assess their methodological quality, as well as to identify the main drivers of the cost effectiveness of pharmacological treatments for the disease. METHODS:A sys...

journal_title：PharmacoEconomics

authors： Rodriguez-Martinez CE,Sossa-Briceño MP,Castro-Rodriguez JA

更新日期：2018-10-01 00:00:00

abstract：:Disease management is a systematic approach to a health condition or a healthcare intervention that organises preventative, interventional and care approaches throughout the continuum of care and which measures outcomes in terms of populations, not individuals. Disease management's advantage over the current component...

journal_title：PharmacoEconomics

authors： Chang K,Nash D

更新日期：1998-07-01 00:00:00